Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Teva Pharmaceutical IndustriesBSP:T1EV34 10 EV-to-FCF is 39.91 as of Jul. 18, 2026, which is 11% below its 10-year median of 44.61. GuruFocus rates BSP:T1EV34 with a GF Score™ of 10/100 and a GF Value™ of R$49.06 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 564 Drug Manufacturers companies, Teva Pharmaceutical Industries ranks worse than 69.68% on this metric.
The historical rank and industry rank for Teva Pharmaceutical Industries's EV-to-FCF or its related term are showing as below:
BSP:T1EV34'
s EV-to-FCF Range Over the Past 10 Years
Min: -958.38 Med: 44.61 Max: 482.95
Current: 43.23
During the past 13 years, the highest EV-to-FCF of Teva Pharmaceutical Industries was 482.95. The lowest was -958.38. And the median was 44.61.
BSP:T1EV34's EV-to-FCF is ranked worse than 69.68% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.815
vs BSP:T1EV34: 43.23
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Teva Pharmaceutical Industries's PE Ratio (TTM) for today is calculated as:
Teva Pharmaceutical Industries's share price for today is R$81.30.
Teva Pharmaceutical Industries's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$3.586.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Teva Pharmaceutical Industries EV-to-FCF Related Terms
Teva Pharmaceutical Industries EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:T1EV34 vs ZTS, UTHR, VTRS: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Teva Pharmaceutical Industries EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Teva Pharmaceutical Industries's EV-to-FCF falls into.
Teva Pharmaceutical Industries's current Enterprise Value is R$256,701 Mil.
Teva Pharmaceutical Industries's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$6,431 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Teva Pharmaceutical Industries (BSP:T1EV34) has a EV-to-FCF of 39.91 as of Jul. 18, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Teva Pharmaceutical Industries and its competitors. This is 11% below median its historical median of 44.61. According to the industry distribution chart, Teva Pharmaceutical Industries ranks #393 out of 564 companies in the Drug Manufacturers industry, placing it in the top 69.7%.
Is Teva Pharmaceutical Industries' EV-to-FCF too high?
Teva Pharmaceutical Industries' current EV-to-FCF of 39.91 is 11% below median its 10-year median of 44.61. The Drug Manufacturers industry median EV-to-FCF is 20.82. Teva Pharmaceutical Industries' value of 39.91 is 91.7% above this industry median. Based on the distribution chart, Teva Pharmaceutical Industries ranks #393 out of 564 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Teva Pharmaceutical Industries has a GF Score™ of 10/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Teva Pharmaceutical Industries ranks #393 out of 564 companies for EV-to-FCF. This places Teva Pharmaceutical Industries in the lower half of its industry. The industry median EV-to-FCF is 20.82. Teva Pharmaceutical Industries' value of 39.91 is 91.7% above this benchmark. While the company's 10-year median is 44.61 vs. the industry median of 20.82, Teva Pharmaceutical Industries has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.82, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Teva Pharmaceutical Industries's current EV-to-FCF of 39.91 is 91.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Teva Pharmaceutical Industries and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Teva Pharmaceutical Industries's current EV-to-FCF is 39.91, which is 11% below median its own 10-year median of 44.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (BSP:T1EV34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$49.06, compared to a current price of R$81.30 — trading 65.7% above its estimated fair value. The current EV-to-FCF is 39.91, which is 11% below median its 10-year median of 44.61 and 91.7% above the Drug Manufacturers industry median of 20.82. Teva Pharmaceutical Industries' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Teva Pharmaceutical Industries (BSP:T1EV34), the current EV-to-FCF is 39.91 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Teva Pharmaceutical Industries (BSP:T1EV34) Overvalued in 2026?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued.
The current stock price of R$81.30 is trading 65.7% above its estimated GF Value™ of R$49.06.
GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.
Key valuation signals for BSP:T1EV34:
EV-to-FCF: 39.91 (11% below median its 10-year median of 44.61)
GF Value™: R$49.06 vs. price of R$81.30 (65.7% above fair value)
Industry Position: 91.7% above the Drug Manufacturers median (#393 of 564)
No single metric tells the full story. See the BSP:T1EV34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Teva Pharmaceutical Industries Business Description
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
10GF Score
Get the complete analysis for BSP:T1EV34
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:T1EV34 has been successfully added to your 
